The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class ...
Vertex Pharmaceuticals on Thursday won approval from the Food and Drug Administration for a non-opioid pain drug, clearing ...
Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration has approved JOURNAVX, an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
Shares of Vertex Pharmaceuticals rose 8% in off-hours trading after the pharmaceutical company won U.S. approval for the [first new non-opioid painkiller in decades]( ...